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 2 
Abstract	
	
The	mouse	pituitary	gland	secretes	hormones	that	regulate	many	physiological	
processes	including	growth,	stress	response,	and	reproduction.	The	canonical	WNT	
signaling	pathway,	activation	of	which	results	in	nuclear	accumulation	of	β-CATENIN	and	
transcription	of	target	genes	including	LEF1,	is	crucial	for	proper	development	of	the	
pituitary	gland.	Pituitary	progenitors	that	lack	β-CATENIN	at	embryonic	day	of	
development	8.5	(E8.5)	cannot	form	three	of	the	six	cell	types	of	the	anterior	pituitary	
that	produce	growth	hormone	(GH),	thyroid	stimulating	hormone	(TSH),	and	prolactin	
(PRL).	Additionally,	stimulating	canonical	WNT	signaling	through	creation	of	
degradation-resistant	β-CATENIN	at	E9.5	causes	pituitary	tumors	and	results	in	a	
reduction	in	the	number	of	GH	and	TSH	secreting	cells.	However,	if	canonical	WNT	
signaling	is	stimulated	in	differentiating	pituitary	cells	at	E14.5,	there	is	no	loss	of	
hormone	cell	types	or	tumor	formation,	demonstrating	that	the	timing	of	the	signaling	is	
critical.	Based	on	these	results	we	chose	to	activate	canonical	WNT	signaling	at	E11.5	in	
pituitary	progenitors	by	creating	a	degradation-resistant	β-CATENIN	using	a	Cre/loxP	
strategy	to	excise	a	portion	of	β-CATENIN	exon	3	necessary	for	normal	degradation.	We	
found	that	activation	of	canonical	WNT	signaling	at	E11.5	resulted	in	hyperplastic	
pituitaries,	increased	epithelial-like	tissue,	and	complete	loss	of	all	hormone-producing	
cell	lineages.	Our	results	demonstrate	that	proper	regulation	and	timing	of	canonical	
WNT	signaling	during	pituitary	development	is	critical	for	proper	differentiation	of	
pituitary	progenitors	into	hormone	cell	types.	
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Introduction	
 The	pituitary	gland,	referred	to	as	the	“master	gland”	of	the	body	due	to	its	
influence	on	other	endocrine	glands,	regulates	a	host	of	physiological	processes	
including	growth,	metabolism,	sexual	development,	and	long-term	stress	response.	
Connected	to	the	hypothalamus	by	the	infundibular	stalk,	the	mouse	pituitary	is	
comprised	of	the	anterior,	posterior,	and	intermediate	lobes,	each	populated	by	a	
unique	group	of	hormone-producing	cell	types.	The	anterior	pituitary’s	somatotrophs,	
thyrotrophs,	corticotrophs,	lactotrophs,	and	gonadotrophs	respectively	secrete	growth	
hormone	(GH),	thyroid-stimulating	hormone	(TSH),	adrenocorticotrophic	hormone	
(ACTH),	prolactin	(PRL),	and	the	gonadotrophic	hormones,	luteinizing	hormone	(LH)	and	
follicle-stimulating	hormone	(FSH).	The	posterior	lobe,	meanwhile,	stores	and	secretes	
antidiuretic	hormone	and	oxytocin	(both	synthesized	by	the	hypothalamus).	In	mice,	the	
intermediate	lobe’s	hormone	cell	types	secrete	melanocyte-stimulating	hormone	
(MSH).	In	humans,	however,	the	intermediate	lobe	is	rudimentary	and	reduced,	and	the	
melanotrophs	are	mixed	into	the	anterior	lobe.	
	
Pituitary	disease	
	 Due	to	the	wide	range	of	processes	under	the	control	of	the	pituitary,	disruption	
to	normal	pituitary	function	can	cause	a	wide	range	of	phenotypes.	For	example,	
deficiency	or	absence	of	any	of	the	hormone-producing	cell	types	is	characteristic	of	
hypopituitarism	and	can	cause	dwarfism	in	the	absence	of	GH	or	adrenal	insufficiency	in	
the	absence	of	ACTH.	A	combination	of	GH	deficiency	with	deficiency	in	any	other	
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hormone	cell	type	constitutes	diagnosis	of	combined	pituitary	hormone	disease	(CPHD),	
a	rare	condition	in	humans	most	often	caused	by	mutations	in	Prophet	of	Pit1	(PROP1),	
the	gene	encoding	a	pituitary-specific	transcription	factor	(Cohen	&	Radovick,	2002).	
The	physiological	deficits	observed	in	individuals	with	CPHD	depend	on	which	hormones	
are	absent,	but	can	include	short	stature,	fatigue,	delayed	puberty,	infertility,	and	
intellectual	disability	in	rare	cases.		
	 Conversely,	problems	can	arise	due	to	oversecretion	of	pituitary	hormones.	
Adenomas	are	benign,	slow-growing	pituitary	tumors	that	secrete	excess	hormones,	
causing	a	variety	of	physiological	effects	dependent	on	the	particular	hormone	secreted	
(Sharif-Alhoseini	&	Rahimi-Movaghar,	2012).	Adenomas	secreting	GH,	for	instance,	can	
result	in	acromegaly	or	gigantism.	Additionally,	an	adenoma	secreting	excess	ACTH	can	
result	in	Cushing’s	Disease,	characterized	by	weight	gain,	impaired	immune	response,	
and	fat	deposits	around	the	neck	or	face.		
		
Early	pituitary	development	
	 During	embryonic	development,	the	pituitary	gland	is	produced	from	two	
ectodermal	tissues:	the	oral	ectoderm	and	the	neural	ectoderm.	At	approximately	
halfway	through	mouse	gestation	on	embryonic	day	of	development	9.5	(E9.5),	cells	of	
the	anterior	pituitary	placode	in	the	oral	ectoderm	invaginate	to	form	Rathke’s	pouch,	
the	precursor	to	the	anterior	and	intermediate	lobes	(Scully	and	Rosenfield,	2002).	
Formation	of	Rathke’s	pouch	creates	a	lumen	surrounded	by	cells	maintaining	an	
epithelial	structure.	The	posterior	pituitary	forms	from	the	ventral	diencephalon,	which	
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evaginates	around	E10,	forming	an	infundibulum,	and	directly	contacts	dorsal	regions	of	
Rathke’s	pouch.	Proteins	expressed	in	this	infundibular	region	act	as	a	signaling	and	
organizing	center	that	is	necessary	for	the	development	of	Rathke’s	pouch	(Scully	and	
Rosenfield,	2002).	Figure	1	shows	a	basic	timeline	of	pituitary	formation	from	the	
invagination	of	the	oral	ectoderm	into	Rathke’s	pouch	and	initial	formation	of	the	
anterior	lobe	between	E10.5	to	E14.5.	
	
Extrinsic	signaling	required	for	pituitary	organogenesis	and	development	
Initial	patterning	and	formation	of	Rathke’s	pouch	is	mediated	by	expression	of	
extrinsic	signaling	molecules	from	the	ventral	diencephalon	and	oral	ectoderm	at	E9.	
Signals	from	the	ventral	diencephalon	include	members	of	the	bone	morphogenetic	
protein	and	fibroblast	growth	factor	families	(BMP4,	FGF8,	and	FGF10).	Meanwhile,	
sonic	hedgehog	(SHH)	is	expressed	in	the	ventral	diencephalon	in	a	domain	adjacent	to	
BMP4	and	the	FGFs	and	also	in	the	oral	ectoderm,	except	in	region	destined	to	become	
Rathke’s	pouch	(Treier	et	al.,	1998).	Disruption	of	this	delicate	coordination	of	signaling	
factors	inhibits	genesis	and	growth	of	Rathke’s	pouch.	For	instance,	loss	of	BMP4	causes	
failure	of	Rathke’s	pouch	formation.	Additionally,	sustained	overexpression	of	FGF8	
within	the	developing	pituitary	causes	excess	proliferation,	enlarged	pituitaries,	and	
absence	of	cell	lineages	including	gonadotropes,	thyrotropes,	somatotropes,	and	
lactotropes	(Treier	et	al.,	1998).	
	
Transcription	factors	required	for	pituitary	organogenesis	and	development	
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	 Apart	from	signaling	molecules,	pituitary	development	is	also	controlled	by	the	
presence	of	transcription	factors	in	Rathke’s	pouch.	These	transcription	factors	are	
particularly	important	for	mediating	the	transition	from	a	proliferating	progenitor	state	
to	the	mature	hormone-producing	cell	types	of	the	anterior	lobe.	PITX1	and	PITX2	are	
expressed	in	the	oral	ectoderm	before	E8.5	and	play	roles	in	limb	development	as	well	
as	in	the	expansion	and	differentiation	of	the	pituitary	progenitor	pool	shortly	after	
Rathke’s	pouch	formation	(Zhu	&	Rosenfield,	2004).	Notably,	the	homeobox	protein	
HESX1,	expressed	beginning	at	E8.5,	is	crucial	for	invagination	of	the	oral	ectoderm	and	
acts	as	a	general	transcriptional	repressor	proposed	to	restrict	FGF	expression	such	that	
only	a	single	invagination	of	Rathke’s	pouch	occurs	(Rizzoti	and	Lovell-Badge,	2005).	
Between	E11.5	and	E13.5,	anterior	lobe	progenitors	exit	the	cell	cycle	and	begin	to	
differentiate,	all	while	leaving	the	epithelium	of	the	pituitary	lumen	and	entering	the	
developing	anterior	lobe	(Davis	et	al.,	2011).	Transcription	factors	including	Prophet	of	
Pit1	(PROP1),	POU	domain,	class	1,	transcription	factor	1	(POUF1),	steroidogenic	factor	1	
(SF1),	and	T-box	transcription	factor	19	(TBX19)	modulate	this	transition	from	
progenitor	to	differentiated	cell	type.	Beginning	at	E10.5,	PROP1,	the	first	pituitary-
specific	transcription	factor,	begins	to	be	expressed.	Importantly,	all	hormone-producing	
cell	types	from	the	intermediate	and	anterior	lobes	derive	from	PROP1-positive	
progenitor	cells,	demonstrating	that	there	is	a	common	pool	of	progenitor	cells	for	all	
hormone	cell	types	(Davis	et	al.,	2016).	Additionally,	PROP1	silences	HESX1	expression	
and	directly	activates	POUF1,	the	signature	transcription	factor	that	gives	rise	to	the	cell	
lineage	that	will	produce	somatotrophs,	lactotrophs,	and	thyrotrophs	(Olson	et	al.,	
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2006).	Mutations	in	PROP1	and	POU1F1	are	implicated	in	human	combined	pituitary	
hormone	deficiency	(CPHD),	a	disorder	characterized	by	deficiencies	in	GH	and	at	least	
one	other	hormone.	Mutations	in	PROP1	are	the	most	common	genetic	cause	of	CPHD,	
accounting	for	approximately	50	percent	of	all	cases	of	CPHD	with	over	15	distinct	
mutations	identified	across	numerous	individuals,	pedigrees,	and	countries	of	origin	
(Deladoëy	et.	al,	1999).	Likewise,	POU1F1	mutations	have	been	described	in	46	patients	
from	34	families	from	a	wide	range	of	countries	of	origin;	all	described	cases	are	similar	
phenotypically	in	their	deficiency	in	GH,	TSH,	and	PRL	(Cohen	&	Radovick,	2002).	
At	the	same	time	POU1F1	becomes	active	in	the	somatotrophs,	lactotrophs,	and	
thyrotroph	lineages,	transcription	factors	SF1	and	TBX19	likewise	become	active	in	their	
respective	subset	of	PROP1-positive	pituitary	progenitors.	SF1	regulates	transcription	of	
genes	related	to	sexual	development	and	characterizes	the	gonadotroph	lineage	that	
secretes	FSH	and	LH	(Ingraham	et	al.,	1994).	Additionally,	TBX19	is	expressed	in	the	
pituitary	pro-opiomelanocortin	cell	lineage	that	produces	corticotrophs	and	
melanocyte-stimulating	hormone	(MSH)	–	producing	melanotrophs	(Lamolet	et	al.,	
2001).	Mutations	in	these	lineage	markers	of	differentiation	can	result	in	loss	of	the	
hormone-producing	cell	type	lineage	associated	with	each	transcription	factor	
(Ingraham	et	al.,	1994;	Lamolet	et	al.,	2001).	Figure	2	shows	a	timeline	of	pituitary	
development,	emphasizing	the	temporal	expression	of	specific	transcription	factors	in	
the	differentiation	of	pituitary	progenitors	to	hormone	producing	cell	types.	
	
Canonical	WNT	signaling	and	pituitary	development	
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	 The	WNT	signaling	pathway	is	crucial	for	numerous	developmental	processes	
during	embryogenesis	and	adult	tissues,	with	effects	ranging	from	cell	proliferation	to	
differentiation	(Logan	&	Nusse,	2004).	Non-canonical	WNT	signaling	pathways	function	
to	regulate	the	cytoskeleton	and	to	control	intracellular	calcium	levels.	Canonical	WNT	
signaling	is	associated	with	the	protein	β-CATENIN,	which	forms	complexes	with	
transcription	factors	in	the	lymphoid	enhancer	binding	factor	(LEF)	and	TCF	DNA	binding	
protein	families	to	regulate	transcription.	When	a	WNT	protein	binds	to	its	Frizzled	
receptor,	the	signal	is	transduced	to	intracellular	proteins	including	the	protein	kinase	
GSK-3,	APC,	AXIN,	and	β-CATENIN	(Logan	&	Nusse,	2004).	Normally,	cytoplasmic	β-
CATENIN	levels	are	kept	low	by	degradation	through	a	GSK-3/APC/AXIN	degradation	
complex.	When	a	cell	binds	a	WNT	ligand,	the	degradation	complex	is	inhibited	and	β-
CATENIN	is	allowed	to	accumulate,	translocate	to	the	nucleus,	and	bind	its	
transcriptional	targets	in	combination	with	LEF/TCF	cofactors.	Figure	3	shows	a	
schematic	of	the	canonical	WNT	pathway	in	cells.	In	the	mouse,	knockout	of	various	
WNT	family	ligands	produces	phenotypes	ranging	from	truncated	limbs	to	infertility	to	
reduction	in	neural	precursors	to	gastrulation	defects;	these	defects	are	all	rooted	in	
reduced	cell	proliferation,	indicating	the	importance	of	WNT	signaling	in	regulating	cell	
proliferation	(Logan	&	Nusse,	2004).	Conversely,	mutations	that	activate	WNT	signaling	
have	been	linked	to	cancer.	Mutations	in	APC	and	CTNNB1	(the	gene	encoding	β-
CATENIN	protein)	are	known	to	cause	approximately	90%	of	all	sporadic	colorectal	
cancers	(Giles	et	al.,	2003).	Other	activating	mutations	in	WNT	signaling	are	linked	to	
cancers	including	gastrointestinal	tumors	outside	the	large	intestine,	melanomas,	and	
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pilomatricomas,	a	benign	skin	tumor	derived	from	the	hair	matrix	(Giles	et	al.,	2003).	In	
most	cases,	activating	CTNNB1	mutations	occur	in	or	around	exon	3,	affecting	the	
phosphorylation	sites	GSK	uses	to	degrade	β-CATENIN,	allowing	the	transcription	factor	
to	accumulate	unchecked	in	the	nucleus	(Giles	et	al.,	2003).	
	
Role	of	β-CATENIN	in	pituitary	development	and	differentiation	of	pituitary	progenitors	
Previous	studies	have	sought	to	understand	how	the	timing	of	WNT	signaling	
and	β-CATENIN	activity	is	important	for	pituitary	development.	Conditional	knockout	of	
β-CATENIN	using	Pitx1-Cre	(at	approximately	E9.5)	results	in	the	loss	of	POU1F1	
expression	and	the	POU1F1	lineage,	indicating	that	β-CATENIN,	together	with	PROP1,	is	
necessary	to	activate	Pou1f1	expression	(Olson	et	al.,	2006).	Indeed,	β-CATENIN	and	
PROP1	form	a	complex	together	through	interactions	of	the	C-terminal	60	amino	acid	
domain	of	PROP1	and	the	full-length	β-CATENIN	(Olson	et	al.,	2006).	While	β-CATENIN	
assists	in	activating	Pou1f1	expression,	it	has	no	role	in	the	maintenance	of	Pou1f1	
expression	later	in	development;	knockout	of	β-CATENIN	later	at	E13.5	in	the	POU1F1	
lineage	using	Pou1f1-Cre	causes	no	phenotypic	change.	Additionally,	β-CATENIN,	
associated	in	a	complex	with	PROP1,	likewise	assists	in	PROP1’s	crucial	role	of	repressing	
Hesx1	(Olson	et	al.,	2006).	Premature	expression	of	β-catenin	resulted	in	absence	of	
Hesx1	expression	at	E9.5	and	lack	of	a	pituitary	gland	at	E13.5.	Further,	chromatin	
immunoprecipation	in	E12.5	pituitaries	revealed	presence	of	both	PROP1	and	β-
CATENIN	in	Hesx1	gene	regulatory	regions	(Olson	et	al.,	2006).	Together,	these	results	
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confirm	β-CANENIN’s	crucial	role	in	activating	and	silencing	gene	expression	during	
pituitary	development.		
To	understand	the	effect	of	activating	canonical	WNT	signaling	during	
development,	researchers	have	created	a	degradation-resistant	β-CATENIN	through	the	
use	of	a	Cre-lox	strategy	which,	upon	the	expression	of	CRE,	excises	a	portion	of	exon	3	
crucial	for	GSK-mediated	degradation,	similar	to	the	mutations	observed	in	human	
cancers.	To	examine	the	effect	of	ectopic	WNT	signaling	during	pituitary	development,	
one	experiment	used	a	Hesx1-Cre	recombinase	to	activate	canonical	WNT	signaling	in	
Rathke’s	pouch	progenitors	expressing	HESX1	(Gaston-Massuet	et	al.,	2011).	
Surprisingly	in	these	mutant	mice,	β-CATENIN	activation	was	localized	to	small	foci	of	
Rathke’s	pouch	progenitors	instead	of	demonstrating	widespread	expression	in	every	
Hesx1-positive	cell.	Additionally,	transcription	of	Lef1,	a	transcriptional	partner	of	β-
CATENIN	that	is	also	transcriptionally	activated	by	canonical	WNT	signaling,	increased	
and	was	likewise	organized	into	discrete	foci.	Further,	post-mortem	examination	of	mice	
expressing	the	activated	β-CATENIN	revealed	they	developed	pituitary	tumors	
(adamantinomatous	craniopharyngioma	[ACP])	and	had	reduced	numbers	of	
somatotrophs	and	thyrotrophs.	Since	Pou1f1	expression	is	crucial	for	further	
differentiation	of	cells	into	somatotrophs	and	thyrotrophs,	the	loss	of	Pou1f1	in	this	
experiment	explains	the	lack	of	differentiation	into	mature	hormone-producing	cells	in	
the	POU1F1	lineage.	This	same	report	also	described	activation	of	β-CATENIN	at	later	
time	points	in	committed	Pou1f1+	cells	or	terminally	differentiated	GH-producing	and	
PRL-producing	cells,	which	resulted	in	the	development	of	normal	adult	pituitaries	
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without	ACP	(Gaston-Massuet	et	al.,	2011).	Thus,	while	activating	WNT	signaling	with	
Hesx1-Cre	(at	approximately	E9.5)	causes	a	recognizable	ACP	phenotype,	activating	WNT	
signaling	later	in	development	in	lineage-committed	progenitors	or	mature	hormone-
producing	cells	is	not	tumorigenic	and	results	in	normal	pituitary	structure	and	function	
(Gaston-Massuet	et	al.,	2011).	These	results	indicate	that	proper	timing	of	canonical	
WNT	signaling	plays	a	role	in	ACP	tumorgenesis	and	the	differentiation	of	pituitary	
progenitors	to	hormone-producing	cell	types	in	mice.	In	human	cases	of	ACP,	over	75%	
(n=121)	exhibit	mutations	in	exon	3	of	the	CTTNB1	gene	encoding	β-CATENIN	(Goschzik	
et	al.,	2017).	These	results,	in	combination	with	previous	mouse	studies,	show	that	
canonical	WNT	signaling	plays	a	critical	role	in	development	and	differentiation	of	
pituitary	progenitors	through	β-CATENIN’s	silencing	of	Hesx1	expression	and	activation	
of	Pou1f1	expression,	but	some	questions	still	remain.	As	previously	described,	pituitary	
progenitors	are	sensitive	to	β-CATENIN	activated	at	E9.5	using	a	Hesx1-Cre	but	not	later	
in	development	at	E13.5	using	a	Pou1f1-Cre.	However,	activation	of	canonical	WNT	
signaling	has	not	been	studied	during	a	critical	window	of	pituitary	development	(E11.5)	
after	Rathke’s	pouch	has	formed	but	before	the	distinct	hormone	lineages	have	been	
established.	
The	work	described	here	seeks	to	evaluate	the	effect	of	activating	canonical	
WNT	signaling	on	the	development	and	differentiation	of	the	pituitary	using	a	Prop1	
driven	CRE	recombinase.	Prop1	is	expressed	exclusively	in	the	pituitary	at	a	later	time	
point	(approximately	E11.5)	than	Pitx1	and	Hesx1,	but	earlier	than	Pou1f1.	These	
experiments	will	provide	insights	into	the	effects	of	activating	canonical	WNT	signaling	
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at	an	intermediate	time	point	after	Rathke’s	pouch	and	the	pituitary	stem	cell	
population	have	been	established,	but	before	the	POU1F1,	TBX19,	and	SF1	progenitor	
lineages	have	been	established.	We	predict	that	activating	β-CATENIN	at	this	
intermediate	time	point	will	result	in	a	less	severe	phenotype	than	activating	earlier	in	
development	with	the	Hesx1-Cre,	but	will	produce	a	more	severe	phenotype	than	
activating	β-CATENIN	in	committed	progenitors	as	previously	described	with	the	Pou1f1-
Cre.	
	
Methods		
Cre	recombinase	and	mouse	line	
	 To	generate	the	tissue-specific	activation	of	canonical	WNT	signaling,	we	
implemented	a	Cre-loxP	strategy	using	a	promoter	from	Prop1,	a	transcription	factor	
expressed	exclusively	in	the	pituitary	progenitors,	to	drive	the	expression	of	CRE	in	only	
the	pituitary	progenitors	(Davis	et	al.,	2016).	CRE,	a	recombinase	enzyme	derived	from	
the	P1	bacteriophage,	recognizes	a	34-base	pair	sequence	called	loxP	sites	and	functions	
to	bring	two	loxP	sites	together	for	recombination	(Kos,	2004).	Depending	on	the	
location	and	orientation	of	loxP	sites,	a	variety	of	genetic	alterations	can	be	
accomplished.	Most	important	for	this	project	is	arranging	the	loxP	sites	so	that	they	are	
flanking	the	target	gene	with	two	loxP	sites	arranged	in	the	same	orientation.	This	
arrangement,	known	as	a	“floxed”	allele,	results	in	excision	of	the	target	sequence	(Kos,	
2004).	In	the	case	of	the	β-catenin,	the	loxP	sites	are	arranged	around	exon	3	such	that	
CRE	recombinase	deletes	exon	3.	The	β-CATENIN	protein	produced	from	the	
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recombined	β-catenin	allele	is	functional,	but	lacks	the	amino	acids	encoded	by	exon	3.	
A	portion	of	exon	3,	containing	the	region	allowing	for	phosphorylation	and	degradation	
by	AXIN,	APC,	and	GSK3,	is	therefore	excised	in	tissues	expressing	the	Prop1	controlled	
CRE	recombinase.	Excising	the	region	responsible	for	degradation	results	in	a	
degradation-resistant	β-CATENIN,	mimicking	the	β-catenin	mutations	found	in	human	
ACP.		
To	generate	a	mouse	line	with	pituitary	specific	canonical	WNT	signaling	
activation,	two	mouse	lines	must	be	crossed:	one	mouse	strain	containing	homozygous	
floxed	alleles	of	β-catenin	(β-cateninGOF/GOF)	and	one	strain	expressing	the	hemizygous	
CRE	recombinase	under	control	of	a	Prop1	promoter	(Prop1-Cre).	This	cross	results	in	
wild	type	embryos	that	do	not	have	the	Prop1-Cre	and	are	heterozygous	for	the	GOF	β-
catenin	allele	and	mutant	embryos	that	are	Prop1-Cre/+;	β-CATENINGOF/+.	The	initiation	
of	embryonic	development	was	determined	by	the	observation	of	a	copulation	plug.	
Noon	of	the	day	the	plug	was	observed	was	established	at	E0.5	as	previously	described	
(Osmundsen	et	al.,	2017).	
	
H&E	and	Immunohistochemistry	
	 Hematoxylin	and	eosin	(H&E)	staining	was	performed	as	previously	described	
(Cardiff	et	al.,	2014).	Mouse	embryos	collected	at	a	variety	of	time	points	were	fixed	in	
4%	paraformaldehyde	overnight	at	4	C,	followed	by	washes	in	phosphate-buffered	
saline	(PBS),	dehydration	in	a	graded	ethanol	series,	and	perfusion	with	paraffin	to	
generate	paraffin	embedded	embryos	for	sectioning	at	6	μm	as	previously	described	
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(Osmundsen	et	al.,	2017).	Slides	used	for	immunohistochemistry	were	prepared	for	
immunostaining	with	sequential	baths	in	xylene	to	remove	paraffin	and	then	hydrated	
with	solutions	of	100%	and	95%	ethanol,	followed	by	PBS.	Immunohistochemistry	was	
performed	as	previously	reported	(Osmundsen	et	al.,	2017).	Table	1	shows	antibodies	
used,	dilution,	species	in	which	the	antibodies	were	generated,	and	amplification	for	
each	experiment.	For	each	immunohistochemistry	protocol,	slides	were	treated	with	
primary	antibody	at	4oC	overnight.	Antibodies	requiring	a	directly	conjugated	secondary	
antibody	are	treated	with	a	secondary	antibody	with	a	fluorescent	tag	and	mounted	
with	fluorescent	mounting	media	for	image	capture.	Primary	antibodies	requiring	
additional	amplification	for	detection	were	treated	with	a	biotinylated	secondary	
antibody	and	then	detected	using	either	a	biotin-binding	streptavidin	covalently	
attached	to	a	florescent	label	or	are	further	amplified	using	a	horseradish	peroxidase-
conjugated	streptavidin,	which	reacts	with	a	tyramide	signal	amplification	reagent	(TSA),	
producing	a	florescent	product.	All	slides	were	counterstained	with	4',6-diamidino-2-
phenylindole	(DAPI).			
	 Notably,	two	different	antibodies	recognizing	β-CATENIN	were	used	in	these	
experiments.	The	mouse	anti-β-CATENIN	primary	antibody	was	used	when	performing	
double	immunostaining	in	order	to	prevent	cross-reactivity	with	other	primary	
antibodies.	In	addition,	a	directly	conjugated	secondary	antibody	was	used	to	
discriminate	between	areas	of	low	versus	high	β-CATENIN	accumulation.	Only	areas	
with	high	β-CATENIN	accumulation	could	be	detected	using	the	mouse	anti-β-CATENIN	
in	combination	with	a	directly	conjugated	secondary	antibody.	
 15 
	 Apoptosis	was	detected	using	DeadEnd	Fluorometric	
deoxynucleotidyltransferase-mediated	dUTP	nick	end	labeling	(TUNEL)	System	
(Promega,	Madison,	WI),	according	to	the	manufacturer’s	protocol.		
	
Epithelial	Area	Quantification	
	 Using	ImageJ,	we	calculated	the	average	epithelial	area	of	five	sagittal	pituitary	
sections	for	four	wild	type	and	four	mutant	embryos	at	E14.5.	The	five	pituitary	sections	
were	selected	in	order	to	capture	epithelial	area	quantifications	across	the	entire	width	
of	the	pituitary.	Tissues	counted	as	epithelium	was	determined	by	morphology	of	the	
tissue.	The	area	calculations	for	the	five	pituitary	sections	for	each	embryo	were	
averaged	together	to	create	an	average	epithelial	area	for	each	of	the	four	wild	type	and	
four	mutant	pituitaries.	Epithelial	area	values	for	wild	type	and	mutant	pituitaries	were	
compared	using	a	Two-Sample	t-Test	Assuming	Unequal	Variances.	
	
Results	
Prop1-Cre/+;	β-CATENINGOF/+	mutants	have	hyperplastic	pituitaries	and	increased	
epithelial	tissue	
	 To	reveal	morphological	changes	to	the	pituitary	caused	by	activating	canonical	
WNT	signaling	in	pituitary	progenitors,	we	performed	H&E	staining	on	histological	
pituitary	sections.	While	H&E	at	E12.5	revealed	no	significant	difference	in	morphology	
(Fig.	4	a-b),	H&E	at	E14.5	and	E16.5	revealed	mutant	pituitaries	to	be	hyperplastic	and	
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dysmorphic	(Fig.	4	c-f).	Although	Prop1-Cre	is	active	starting	at	E11.5,	morphological	
changes	are	not	seen	in	the	pituitary	until	E14.5	at	the	earliest.		
Mutant	pituitaries	appeared	to	exhibit	a	larger	amount	of	epithelial	tissues,	
confirmed	by	comparing	area	quantification	of	wild	type	and	mutant	embryos	(Fig.	4i).	
Immunostaining	for	cytokeratin8,	a	marker	of	simple	epithelium	found	in	Rathke’s	
pouch,	revealed	a	marked	increase	in	epithelial	cells	in	the	mutant	pituitaries	(Fig.	4	g-
h).		
	
Accumulation	of	β-CATENIN	and	canonical	WNT	signaling	activation	occurs	in	a	subset	of	
PROP1+	pituitary	progenitors		
	 To	determine	when	β-CATENIN	activation	and	accumulation	occurs	after	Prop1-
Cre	recombination,	immunostaining	for	β-CATENIN	was	performed	at	E12.5,	E14.5,	and	
E16.5.	Immunostaining	for	β-CATENIN	notably	revealed	that	β-CATENIN	was	localized	
into	foci	throughout	the	anterior	pituitary	(Fig.	5).	At	E12.5,	small	clusters	of	β-CATENIN	
began	forming	in	the	epithelium	of	the	pituitary	(Fig.	5	a-b).		At	E14.5	and	E16.5,	a	large	
proportion	of	the	pituitary	exhibited	clusters	of	activated	β-CATENIN	(Fig.	5	c-f).	
However,	not	every	cell	or	even	every	epithelial-like	cell	expressed	high	levels	of	β-
CATENIN	even	though	these	cells	express	PROP1,	the	driver	of	the	CRE	recombinase	
which	generates	the	degradation-resistant	β-CATENIN	(Fig.	6).	Additionally,	double	
immunostaining	for	PROP1	and	β-CATENIN	(marked	by	directly	conjugated	β-CATENIN	
as	described	earlier	to	detect	only	high	expression	of	β-CATENIN)	revealed	that	PROP1	is	
only	expressed	in	cells	that	do	not	have	high	levels	of	β-CATENIN	(Fig.	6	c-e).	These	
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results	indicate	that	not	every	PROP1+	pituitary	progenitor	express	the	activated	β-
CATENIN	and	suggests,	together	with	similar	findings	in	Hesx1-Cre	mutants	where	β-
CATENIN	is	localized	to	small	foci,	some	mechanism	that	can	potentially	limit	
accumulation	of	β-CATENIN	in	some	pituitary	progenitors.			
	 To	ensure	canonical	WNT	signaling	was	stimulated	by	the	activated	β-CATENIN	
protein,	we	performed	immunostaining	for	LEF1,	which	forms	a	complex	with	β-
CATENIN	and	is	also	transcriptionally	activated	by	canonical	WNT	signaling.	Staining	at	
E16.5	revealed	that	LEF1	is	organized	into	discrete	clusters	similar	to	β-CATENIN	and	
that	LEF1	appears	in	discrete	foci	as	early	as	E12.5,	a	time	point	where	LEF1	is	not	
normally	expressed	(Fig.	7	a-d).	Double	immunostaining	for	β-CATENIN	using	the	mouse	
anti-β-CATENIN	antibody	with	a	directly	conjugated	secondary	antibody	(to	detect	only	
regions	of	high	β-CATENIN	expression)	and	LEF1	at	E14.5	revealed	that	LEF1	is	localized	
to	regions	of	high	β-CATENIN	expression,	indicating	that	canonical	WNT	signaling	is	
active,	leading	to	the	transcription	of	LEF1	and	other	targets	of	β-CATENIN	(Fig.	7	e-f).		
	
Cells	with	high	levels	of	activated	β-CATENIN	do	not	express	pituitary	stem	cell	markers	
or	markers	of	proliferation	
	 In	order	to	better	characterize	the	high-	β-CATENIN	clusters	formed	in	Prop1-
Cre/+;	β-CATENINGOF/+	mutant	pituitaries,	we	performed	immunostaining	for	SOX2,	
SOX9,	Ki67,	and	CYCLIN	D2,	markers	of	stemness	and	proliferation	previously	studied	in	
relation	to	the	ACP	phenotype	(Gaston-Massuet	et	al.,	2011)	(Fig.	8).	While	some	cells	
with	epithelial-like	morphology	in	mutant	pituitaries	express	SOX2	or	SOX9,	cells	with	
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high	levels	of	β-CATENIN	(marked	by	directly	conjugated	β-CATENIN	as	described	
earlier)	failed	to	express	SOX2	or	SOX9,	indicating	they	are	not	pituitary	progenitor	cells	
(Fig.	8	b	&	d).	Likewise,	regions	of	high	β-CATENIN	expression	did	not	express	the	
markers	of	proliferation	Ki67	and	CYCLIN	D2,	indicating	they	are	in	a	quiescent,	non-
proliferative	state	(Fig.	8	f	&	h).	Further,	little	to	no	cells	in	the	mutant	pituitaries	are	
apoptotic,	indicating	that	activating	canonical	WNT	signaling	does	not	result	in	increased	
cell	death	(Fig.	8	i-j).	
	
Prop1-Cre/+;	β-CATENINGOF/+	pituitaries	do	not	express	lineage	markers	and	fail	to	
produce	hormones	
	 To	understand	how	activating	β-CATENIN	in	pituitary	progenitors	affects	the	
differentiation	from	a	progenitor	state	into	hormone-producing	cell	types,	we	
performed	immunostaining	at	E16.5	for	POU1F1,	SF1,	and	TBX19,	markers	of	the	three	
distinct	cell	lineages	that	populate	the	mature	anterior	pituitary.	Expression	of	the	
lineage	markers	were	completely	absent	in	the	Prop1-Cre/+;	β-CATENINGOF/+	pituitaries,	
indicating	differentiation	has	been	severely	affected	by	stimulating	canonical	WNT	
signaling	(Fig.	9	a-f).	Since	the	lineage	markers	are	required	for	terminal	differentiation	
into	hormone-producing	cells,	one	would	predict	the	absence	of	hormones	in	the	
mature	pituitary.	Immunostaining	for	hormone	markers	at	E18.5	revealed	the	absence	
of	GH,	TSH,	LH,	and	ACTH	(Fig.	10	a-h).		
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Discussion	
	 In	this	study,	we	show	that	activation	of	canonical	WNT	signaling	in	the	mouse	
pituitary	progenitors	inhibits	differentiation	of	pituitary	progenitors	into	hormone	
producing	cell	types	and	causes	excess	epithelial	structures	beginning	at	E14.5.	Prop1-
Cre/+;	β-CATENINGOF/+	mutants	do	not	express	POU1F1,	TBX19,	or	SF1,	markers	of	the	
distinct	cell	lineages	that	give	rise	to	all	hormone-producing	cell	types	of	the	anterior	
pituitary	and	additionally	fail	to	express	any	hormones,	indicating	that	activation	of	
canonical	WNT	signaling	can	inhibit	progenitor	cell	differentiation.			
	 Our	results,	combined	with	the	wider	body	of	research,	indicate	that	the	timing	
of	canonical	WNT	signaling	activation	is	crucial	for	pituitary	gland	development.	One	
previous	study,	using	a	Hesx1	driven	CRE	in	combination	with	a	β-CATENIN	gain-of-
function	allele	to	achieve	canonical	WNT	signaling	activation	at	E8.5,	resulted	in	a	
phenotype	similar	to	human	ACP,	a	pituitary	tumor	derived	from	undifferentiated	
progenitor	cells	(Gaston-Massuet	et	al.,	2011).	Activation	of	canonical	WNT	signaling	at	
this	time	point	also	inhibited	the	expression	of	Pou1f1	and	resulted	in	a	decrease	in	the	
number	of	somatotrophs	and	thyrotrophs	(Gaston-Massuet	et	al.,	2011).	ACTH	and	CGA	
(marking	LH,	FSH,	and	TSH,	heterodimers	which	share	a	common	alpha	subunit)	were	
still	expressed,	demonstrating	that	activation	of	canonical	WNT	signaling	does	not	result	
in	a	complete	loss	of	hormone	cell	types.	However,	activating	canonical	WNT	signaling	
later	in	development	around	E14.5	in	committed	progenitors	using	a	Pou1f1	driven	CRE	
results	in	a	normal	pituitary	phenotype	with	no	observable	effect	on	differentiation.	The	
data	presented	here	reflect	the	activation	of	canonical	WNT	signaling	at	an	intermediate	
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time	point	using	a	Prop1	driven	CRE,	active	beginning	at	E11.5.	Somewhat unexpectedly,	
activating	canonical	WNT	signaling	at	this	intermediate	time	point	causes	a	more	severe	
phenotype	than	activating	at	E8.5,	using	the	Hesx1-Cre.	Our	manipulation	resulted	in	
the	complete	loss	of	the	cell	lineages	that	give	rise	to	all	hormone-producing	cell	types	
in	the	anterior	pituitary	and	resulted	in	gross	structural	defects	in	the	mutant	pituitaries.		
	 Similarly	to	the	Hesx1-Cre	study,	activating	canonical	WNT	signaling	resulted	in	
the	accumulation	of	β-CATENIN	in	a	subset	of	cells	in	the	pituitary.	However,	the	high-β-
CATENIN	regions	in	our	study	where	markedly	different	from	the	ACP	phenotype	seen	
previously	(Gaston-Massuet	et	al.,	2011).	ACP	regions	in	the	Hesx1-Cre	study	express	
SOX2	and	CYCLIND2	while	cells	on	the	periphery	of	the	tumors	express	SOX9	and	Ki67.	
In	this	study,	areas	outside	of	the	high-β-CATENIN	regions	express	all	of	these	markers,	
indicating	that	they	are	pituitary	progenitors;	however,	high-β-CATENIN	regions	do	not	
express	SOX2,	SOX9,	Ki67,	or	CYCLIND2,	indicating	that	later	timing	of	canonical	WNT	
signaling	activation	shifts	the	pituitary	progenitors	away	from	a	pituitary	identity.	While	
Prop1-Cre/+;	β-CATENINGOF/+	embryos	do	not	express	markers	of	ACP	seen	previously,	
our	phenotype	is	similar	in	ways	to	the	tumors	created	when	activating	β-CATENIN	in	
Sox2+	cells	using	an	tomoxifen-indu	tomoxifin	cible	CRE	(Andoniadou	et	al.,	2013).	In	
particular,	this	group	found	nuclear	accumulation	of	β-CATENIN	in	foci	surrounded	by	
cells	exhibiting	normal	β-CATENIN	accumulation.	Additionally,	these	tumors	were	
undifferentiated,	lacking	POU1F1	and	SOX9	in	the	foci	and	were	quiescent,	proven	by	a	
lack	of	Ki67	in	the	foci	(Andoniadou	et	al.,	2013).	Together,	these	results	indicate	that	
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activation	of	canonical	WNT	signaling	during	pituitary	development	has	tumorigenic	
potential.		
	 In	addition	to	the	more	severe	disruption	of	differentiation	of	progenitor	cells,	
activation	of	canonical	WNT	signaling	at	E11.5	with	a	Prop1-Cre	results	in	a	significant	
increase	in	epithelial	area,	a	phenotype	not	seen	when	activating	canonical	WNT	
signaling	earlier	in	development	at	E9.5.	This	increase	in	epithelial	cells	indicates	that	
activation	of	canonical	WNT	may	play	a	role	in	inhibiting	the	transition	of	the	pituitary	
progenitor	from	an	epithelial	morphology	to	the	more	mature	epithelioid	structure	that	
characterizes	the	parenchyma	of	the	adult	anterior	pituitary.		
	 Our	results	also	demonstrate	a	previously	unreported	result	of	increased	
canonical	WNT	signaling	–	the	repression	of	Prop1.	In	this	study,	areas	with	high	β-
CATENIN	fail	to	express	PROP1,	a	marker	of	pituitary	progenitors,	suggesting	a	dual	role	
for	β-CATENIN	in	relation	to	PROP1.	PROP1	and	β-CATENIN	form	a	complex	that	both	
represses	Hesx1	and	activates	Pou1f1,	but	our	results	indicate	that	sufficiently	high	
levels	of	β-CATENIN	can	also	inhibit	the	expression	of	Prop1.	Combined	with	the	
absence	of	pituitary	stem	cell	markers,	SOX2	and	SOX9,	this	result	also	demonstrates	
that	Prop1-Cre+	cells	are	susceptible	to	high	levels	of	canonical	WNT	signaling,	which	can	
shift	these	cells	away	from	a	pituitary	identity.			
	 These	results	help	to	show	the	effect	that	presence	and	timing	of	β-CATENIN	and	
canonical	WNT	signaling	have	on	the	development	of	the	pituitary	and	differentiation	of	
progenitors	to	hormone	cell-types.	Conditional	knockout	of	β-CATENIN	at	E9.5	results	in	
the	loss	of	Pou1f1,	revealing	the	key	role	that	β-CATENIN	plays	in	concert	with	PROP1	
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(Olson	et	al.,	2006).	Additionally,	activation	of	β-CATENIN	at	various	time	points	disrupts	
normal	development	and	differentiation	of	the	pituitary.	It	has	been	previously	shown	
that	activating	canonical	WNT	signaling	in	Sox2+	progenitors	or	progenitors	at	E9.5	
disrupt	differentiation	and	are	tumorigenic	but	that	activating	canonical	WNT	signaling	
at	E13.5	when	hormone	lineages	have	been	established	has	no	significant	effect	(Olson	
et	al.,	2006).	Our	results	prove	that	pituitary	progenitors	are	still	sensitive	to	activation	
of	canonical	WNT	signaling	and	that	increased	levels	of	β-CATENIN	cause	catastrophic	
disruptions	to	pituitary	development,	resulting	in	the	loss	of	all	hormone	cell	types	and	
halting	the	transition	from	epithelial	morphology	to	the	mature	morphology	
characteristic	of	the	adult	pituitary	parenchyma.		
	
	
Acknowledgements	
	 This	work	was	supported	in	part	by	the	South	Carolina	Honors	College	Senior	
Thesis/Project	Grant.	This	work	was	also	supported	by	startup	funding	provided	to	
Shannon	Davis	by	the	University	of	South	Carolina.			
	
References	
Andoniadou,	C.	L.,	Matsushima,	D.,	Gharavy,	S.	N.	M.,	Signore,	M.,	Mackintosh,	A.	I.,	
Schaeffer,	M.,	...	&	Dattani,	M.	T.	(2013).	Sox2+	stem/progenitor	cells	in	the	adult	
mouse	pituitary	support	organ	homeostasis	and	have	tumor-inducing	
potential.	Cell	Stem	Cell,	13(4),	433-445.	
Cardiff,	R.	D.,	Miller,	C.	H.,	&	Munn,	R.	J.	(2014).	Manual	hematoxylin	and	eosin	staining	
of	mouse	tissue	sections.	Cold	Spring	Harbor	protocols,	2014(6),	pdb-
prot073411.	
Cohen,	L.	E.,	&	Radovick,	S.	(2002).	Molecular	basis	of	combined	pituitary	hormone	
deficiencies.	Endocrine	Reviews,	23(4),	431-442.	
 23 
Davis,	S.	W.,	Mortensen,	A.	H.,	&	Camper,	S.	A.	(2011).	Birthdating	studies	reshape	
models	for	pituitary	gland	cell	specification.	Developmental	biology,	352(2),	215-
227.	
Davis,	S.	W.,	Ellsworth,	B.	S.,	Millan,	M.	I.	P.,	Gergics,	P.,	Schade,	V.,	Foyouzi,	N.,	...	&	
Camper,	S.	A.	(2013).	Pituitary	gland	development	and	disease:	from	stem	cell	to	
hormone	production.	Current	topics	in	developmental	biology,	106,	1.	
Davis,	S.	W.,	Keisler,	J.	L.,	Pérez-Millán,	M.	I.,	Schade,	V.,	&	Camper,	S.	A.	(2016).	All	
hormone-producing	cell	types	of	the	pituitary	intermediate	and	anterior	lobes	
derive	from	Prop1-expressing	progenitors.	Endocrinology,	157(4),	1385-1396.	
de	Graaff	L.C.G.	(2000).	PROP1-Related	Combined	Pituitary	Hormone	Deficiency.	In:	
Adam	MP,	Ardinger	HH,	Pagon	RA,	et	al.,	editors.	GeneReviews®	[Internet].	
Seattle	(WA):	University	of	Washington,	Seattle;	1993-2018.	Available	from:	
https://www.ncbi.nlm.nih.gov/books/NBK1347/	
Deladoëy,	J.,	Flück,	C.,	Büyükgebiz,	A.,	Kuhlmann,	B.	V.,	Eblé,	A.,	Hindmarsh,	P.	C.,	...	&	
Mullis,	P.	E.	(1999).	“Hot	spot”	in	the	PROP1	gene	responsible	for	combined	
pituitary	hormone	deficiency.	The	Journal	of	Clinical	Endocrinology	&	
Metabolism,	84(5),	1645-1650.	
Gaston-Massuet,	C.,	Andoniadou,	C.	L.,	Signore,	M.,	Jayakody,	S.	A.,	Charolidi,	N.,	
Kyeyune,	R.,	...	&	Dattani,	M.	T.	(2011).	Increased	Wingless	(Wnt)	signaling	in	
pituitary	progenitor/stem	cells	gives	rise	to	pituitary	tumors	in	mice	and	humans.	
Proceedings	of	the	National	Academy	of	Sciences,	108(28),	11482-11487.	
Giles,	R.	H.,	van	Es,	J.	H.,	&	Clevers,	H.	(2003).	Caught	up	in	a	Wnt	storm:	Wnt	signaling	in	
cancer.	Biochimica	et	Biophysica	Acta	(BBA)-Reviews	on	Cancer,	1653(1),	1-24.		
Goschzik,	T.,	Gessi,	M.,	Dreschmann,	V.,	Gebhardt,	U.,	Wang,	L.,	Yamaguchi,	S.,	...	&	
Pietsch,	T.	(2017).	Genomic	alterations	of	adamantinomatous	and	papillary	
craniopharyngioma.	Journal	of	Neuropatholgy	&	Experimental	Neurology,	76(2),	
126-134.	
Ingraham,	H.	A.,	Lala,	D.	S.,	Ikeda,	Y.,	Luo,	X.,	Shen,	W.	H.,	Nachtigal,	M.	W.,	...	&	Parker,	
K.	L.	(1994).	The	nuclear	receptor	steroidogenic	factor	1	acts	at	multiple	levels	of	
the	reproductive	axis.	Genes	&	Development,	8(19),	2302-2312.	
Kos,	C.	H.	(2004).	Methods	in	nutrition	science:	Cre/loxP	system	for	generating	tissue-
specific	knockout	mouse	models.	Nutrition	reviews,	62(6),	243-246.	
Lamolet,	B.,	Pulichino,	A.	M.,	Lamonerie,	T.,	Gauthier,	Y.,	Brue,	T.,	Enjalbert,	A.,	&	
Drouin,	J.	(2001).	A	pituitary	cell-restricted	T	box	factor,	Tpit,	activates	POMC	
transcription	in	cooperation	with	Pitx	homeoproteins.	Cell,	104(6),	849-859.	
Logan,	C.	Y.,	&	Nusse,	R.	(2004).	The	Wnt	signaling	pathway	in	development	and	disease.	
Annu.	Rev.	Cell	Dev.	Biol.,	20,	781-810.	
Olson,	L.	E.,	Tollkuhn,	J.,	Scafoglio,	C.,	Krones,	A.,	Zhang,	J.,	Ohgi,	K.	A.,	...	&	Rose,	D.	
(2006).	Homeodomain-mediated	β-CATENIN-dependent	switching	events	dictate	
cell-lineage	determination.	Cell,	125(3),	593-605.	
Osmundsen,	A.	M.,	Keisler,	J.	L.,	Taketo,	M.	M.,	&	Davis,	S.	W.	(2017).	Canonical	WNT	
signaling	regulates	the	pituitary	organizer	and	pituitary	gland	
formation.	Endocrinology,	158(10),	3339-3353.	
 24 
Rizzoti,	K.,	&	Lovell-Badge,	R.	(2005).	Early	development	of	the	pituitary	gland:	induction	
and	shaping	of	Rathke’s	pouch.	Reviews	in	Endocrine	and	Metabolic	Disorders,	
6(3),	161-172.	
Scully,	K.	M.,	&	Rosenfeld,	M.	G.	(2002).	Pituitary	development:	regulatory	codes	in	
mammalian	organogenesis.	Science,	295(5563),	2231-2235.	
Sharif-Alhoseini,	M.,	&	Rahimi-Movaghar,	V.	(2012).	Pituitary	adenomas:	a	
review.	Journal	of	Injury	and	Violence	Research,	4(3	Suppl	1).	
Treier,	M.,	Gleiberman,	A.	S.,	O’Connell,	S.	M.,	Szeto,	D.	P.,	McMahon,	J.	A.,	McMahon,	
A.	P.,	&	Rosenfeld,	M.	G.	(1998).	Multistep	signaling	requirements	for	pituitary	
organogenesis	in	vivo.	Genes	&	development,	12(11),	1691-1704.	
Zhu,	X.,	&	Rosenfeld,	M.	G.	(2004).	Transcriptional	control	of	precursor	proliferation	in	
the	early	phases	of	pituitary	development.	Current	opinion	in	genetics	&	
development,	14(5),	567-574.	
	
	
	
	
	
	
	
	
	
	 	
 25 
	
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	2.	
Schematic	of	the	
Canonical	WNT	
signaling	pathway	
showing	the	
degradation	of	β-
CATENIN	in	cells	
lacking	WNT	(left)	
and	β-CATENIN	
accumulation	in	
cells	where	a	WNT	
ligand	has	bound	
the	Frizzled	
receptor.	
Figure	1.	Basic	timeline	of	pituitary	development	from	Rathke’s	pouch	formation	(left)	
at	E10	to	E14.5	where	lobes	of	the	pituitary	are	distinct	(right).		
Figure	3.	Timeline	of	pituitary	development	from	E8.5	to	E17.5,	showing	the	
temporal	nature	of	transcription	factor	expression	required	for	progression	from	
a	progenitor	state	to	mature	hormone-producing	cell	type.	
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Figure	4.	Histological	sections	of	
wild	type	and	mutant	mouse	
pituitary	stained	with	
hemotoxilin	and	eosin	at	E12.5	
(a-b),	E14.5	(c-d),	and	E16.5	(e-f)	
time	points.	Beginning	at	E14.5,	
gross	differences	in	morphology	
exist	between	wild	type	and	
mutant	pituitaries.		
Immunostaining	at	E16.5	of	
pituitaries	with	antibodies	for	
Cytokeratin	8	(pink),	an	indicator	
of	simple	epithelium	(g-h).	
Below,	epithelial	area	
quantification	of	wild	type	and		
Prop1-cre;	β-catenin	GOF/+	
pituitaries,	measured	using	
ImageJ	(i).	
Table	1.	Table of antibodies used including dilution, amplification level, and species in which the 
antibody was raised.	
0	
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Normal	Control	 Prop1-cre;	β-cateninGOF/
+	
Ep
ith
el
ia
l	a
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a	
(m
m
2 )
	
Amount	of	Epithelial	Area	(i)	
Target	protein Dilution Amplification	 Antibody	animal	background
B-catenin 1:100 Directly	Conjugated	Secondary Mouse
B-catenin 1:1000 Strep Rabbit
ACTH 1:150 Directly	Conjugated	Secondary Rabbit
Cyclin	D2 1:200 TSA Rabbit
Cytokeratin	8 1:50-1:100 TSA Rabbit
GH 1:100 Directly	Conjugated	Secondary Monkey
Ki67 1:200 Directly	Conjugated	Secondary Rabbit
Lef1 1:500 TSA Goat
LH 1:50 Directly	Conjugated	Secondary Guinea	Pig
Pou1f1 1:500 Directly	Conjugated	Secondary Rabbit
Prop1 1:100 TSA Guinea	Pig
Sf1 1:250 TSA Mouse
Sox2 1:200 TSA Rabbit
Sox9 1:100 Strep Rabbit
Tbx19 1:200 Directly	Conjugated	Secondary Rabbit
TSH 1:100 Directly	Conjugated	Secondary Guinea	Pig
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Figure	5.	Histological	sections	of	wild	type	and	mutant	mouse	pituitary	marked	with	antibody	specific	for	β-catenin	
at	E12.5	(a-b),	E14.5	(c-d),	and	E16.5	(e-f).	At	E12.5,	localization	of	β-catenin	begins	(white	arrows)	and	localization	is	
prominent	at	E14.5	and	E16.5	
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Figure	6.	Double	immunostain	for	PROP1	
and	β-CATENIN	in	wild	type	(a)	and	
mutant	pituitaries	(b).	Area	contained	by	
the	white	box	(b)	is	magnified	for	further	
examination	in	panels	c-e.	PROP1	(d)	is	
only	expressed	in	regions	with	low	
expression	of	β-CATENIN	and	is	absent	in	
high	β-CATENIN	regions	(c).	(e)	shows	a	
double	immunostain	for	PROP1	(red)	and	
β-CATENIN	(green).			
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 Figure	7.	Immunostaining	of	histological	sections	of	wild	type	and	mutant	pituitary	with	an	
antibody	specific	for	LEF1	(a-b),	indicating	stimulation	of	Canonical	WNT	signaling	at	E16.5.	
Immunostain	for	LEF1	at	E12.5	(c-d)	showing	localization	of	LEF1	in	mutant	pituitaries	(white	
arrows).	
Double	immunostaining	for	β-catenin	and	LEF1	at	E14.5	and	E16.5	in	mutant	pituitaries,	
demonstrating	localization	of	LEF1	in	high	β-catenin	regions	(e-f).		
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Figure	8.	Immunostaining	of	histological	sections	of	wild	type	and	mutant	pituitaries	
for	combination	of	β-catenin	and	SOX2	(a-b),	SOX9	(c-d),	Ki67	(e-f),	or	CYCLIN	D2	(g-h)	
as	indicated.	Region	surrounded	by	yellow	indicate	high	β-catenin	regions	that	fail	to	
express	SOX2,	SOX9,	Ki67,	or	CYCLIN	D2,	respectively.	TUNEL	was	performed	at	E14.5	
on	wild	type	and	mutant	pituitaries	to	access	presence	of	apoptosis	(i-j).	
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Figure	9.	Immunostaining	of	
sections	of	wild	type	and	
mutant	pituitaries	with	
antibodies	specific	for	
markers	of	cell	lineages	
POU1F1	(a-b),	SF1	(c-d),	and	
TBX19	(e-f)	at	E16.5	
revealing	the	complete	
absence	of	all	cell	lineage	
markers	in	mutant	
pituitaries.		
	
Figure	10.	Immunostaining	of	sections	of	wild	
type	and	mutant	pituitaries	at	E18.5	with	
antibodies	specific	for	hormones	GH	(a-b),	TSH	
(c-d),	ACTH	(e-f),	and	LH	(g-h).	In	mutant	
pituitaries	at	E18.5,	there	is	a	complete	loss	of	
all	hormones	of	the	anterior	pituitary.		
